These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 39358206)

  • 1. Immunogenicity and immune persistence of Zagreb 2-1-1 regimen of rabies vaccine in Chinese healthy individuals: A randomized, parallel-controlled of homologous vaccine with different immune procedure study.
    Li L; Xu J; Zhang J; Wang F; Cai J; Yang L; Zhu Z; Bai Y; Jia B; Ma J; Shi N; Li S
    Hum Vaccin Immunother; 2024 Dec; 20(1):2403177. PubMed ID: 39358206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study.
    Li R; Li Y; Wen S; Wen H; Nong Y; Mo Z; Xie F; Pellegrini M
    Hum Vaccin Immunother; 2015; 11(2):435-42. PubMed ID: 25692350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of purified vero cell rabies vaccine (PVRV) produced by Liaoning Cheng Da Co. under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese adults aged 50 and above.
    Wang J; Luo F; Feng Z; Li L; Bai Y; Ai X; Ma J; Zhang Z; Shi N
    Hum Vaccin Immunother; 2017 Jan; 13(1):144-150. PubMed ID: 28045585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults.
    Ma J; Wang H; Li J; Chang L; Xie Y; Liu Z; Zhao Y; Malerczyk C
    Hum Vaccin Immunother; 2014; 10(10):2805-12. PubMed ID: 25483635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects.
    Shi N; Zhang Y; Zheng H; Zhu Z; Wang D; Li S; Li Y; Yang L; Zhang J; Bai Y; Lu Q; Zhang Z; Luo F; Yu C; Li L
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-8. PubMed ID: 28121231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of purified vero cell-cultured rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in the healthy Chinese subjects: a randomized, double-blind, positive controlled phase 3 clinical trial.
    Shen H; Wang Z; Yang B; Cai K; Jiang C; Xie R; Xiao H; Ren Q; Qi Z; Li J; Li Q; Ye J; Zhan F
    Hum Vaccin Immunother; 2021 Feb; 17(2):351-357. PubMed ID: 32783769
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of safety and immunogenicity of purified chick embryo cell vaccine using Zagreb and Essen regimens in patients with category II exposure in China.
    Hu Q; Liu MQ; Zhu ZG; Zhu ZR; Lu S
    Hum Vaccin Immunother; 2014; 10(6):1645-9. PubMed ID: 24632727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological Effect of aGV Rabies Vaccine Administered Using the Essen and Zagreb Regimens: A Double-Blind, Randomized Clinical Trial.
    Miao L; Shi L; Yang Y; Yan K; Sun H; Mo Z; Li L
    Viral Immunol; 2018 Apr; 31(3):242-248. PubMed ID: 29394147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study on the immunogenicity and safety of a purified chick embryo cell rabies vaccine (PCECV) administered according to two different simulated post exposure intramuscular regimens (Zagreb versus Essen).
    Mahendra BJ; Narayana DA; Agarkhedkar S; Ravish HS; Harish BR; Agarkhedkar S; Madhusudana SN; Belludi A; Ahmed K; Jonnalagedda R; Vakil H; Bhusal C; Arora AK
    Hum Vaccin Immunother; 2015; 11(2):428-34. PubMed ID: 25692792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic.
    Jin F; Zhu L; Wang Y; Qin G; Tian Y; Xie Y; Jin H; Zhang Y; Wang L; Li J; Wu Z; Sheng Y; Shi L; Yang G; Zhao Z; Chen L; Chen P; Jiang Z; Yu J; Gao Z; Li Q; Wu X; Miao L
    Vaccine; 2024 Oct; 42(23):126059. PubMed ID: 38937182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of 4-dose Essen intramuscular regimen for rabies post-exposure prophylaxis: A multi-center cross-sectional study in China.
    Hou Q; Liu S; Liu C; Wang X; Shi J; Chen Q; Lv X; Zhu Z; Wang C; Yin W
    Travel Med Infect Dis; 2024; 60():102735. PubMed ID: 38992484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Making rabies prophylaxis more economical: immunogenicity and safety results from a preliminary study using a 2-1 intramuscular regimen in healthy volunteers.
    Huang G; Liu H; Tang Q; Yu P; Shen X; Zhang Y; Liu X; Cao Q; Fu C; Liu B; Wang M
    Hum Vaccin Immunother; 2014; 10(1):114-9. PubMed ID: 24008819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity study of a new purified chick embryo cell rabies vaccine Vaxirab-N (Pitman-Moore strain) manufactured in India.
    Ashwath Narayana DH; Madhusudana SN; Sampath G; Tripathy RM; Sudarshan MK; Gangaboraiah ; Ravish HS; Satapathy DM; Gowda G; Holla R; Ashwin BY; Padhi A; Manjula S; Patel PM
    Hum Vaccin Immunother; 2014; 10(1):120-5. PubMed ID: 24030586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis.
    Wongsaroj P; Udomchaisakul P; Tepsumethanon S; Khawplod P; Tantawichien T
    Vaccine; 2013 Mar; 31(13):1748-51. PubMed ID: 23370149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen.
    Ambrozaitis A; Laiskonis A; Balciuniene L; Banzhoff A; Malerczyk C
    Vaccine; 2006 May; 24(19):4116-21. PubMed ID: 16545510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II randomized study to determine the safety and immunogenicity of the novel PIKA rabies vaccine containing the PIKA adjuvant using an accelerated regimen.
    Kalimuddin S; Wijaya L; Chan YFZ; Wong AWL; Oh HML; Wang LF; Kassim JA; Zhao J; Shi Z; Low JG
    Vaccine; 2017 Dec; 35(51):7127-7132. PubMed ID: 29174316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of immunogenicity and safety of human rabies vaccination under Zagreb and Essen regimens.
    Li T; Wang X; Cheng H
    J Comp Eff Res; 2020 May; 9(7):459-468. PubMed ID: 32374178
    [No Abstract]   [Full Text] [Related]  

  • 18. Persistence of rabies antibody 5 years after postexposure prophylaxis with vero cell antirabies vaccine and antibody response to a single booster dose.
    Zhang X; Zhu Z; Wang C
    Clin Vaccine Immunol; 2011 Sep; 18(9):1477-9. PubMed ID: 21752947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-marketing immunogenicity and safety of a lyophilized purified human diploid cell rabies vaccine produced from microcarrier cultures: a randomized clinical trial.
    Zhou X; Wu X; Cai Y; Cao S; Zhu X; Lv Q; Chen H; Shi L; Li J; Wang X; Li Y; Zhou R
    Hum Vaccin Immunother; 2019; 15(4):828-833. PubMed ID: 30457436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series.
    Cramer JP; Jelinek T; Paulke-Korinek M; Reisinger EC; Dieckmann S; Alberer M; Bühler S; Bosse D; Meyer S; Fragapane E; Costantini M; Pellegrini M; Lattanzi M; Dovali C
    J Travel Med; 2016 Mar; 23(3):. PubMed ID: 26994987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.